JPRN-UMIN000052546尚未招募Unknown
Phase II trial to evaluate the feasibility of preoperative weight loss program for obese patients with gastric cancer - Phase II trial to evaluate the feasibility of preoperative weight loss program
Gastric Surgery, Department of Gastroenterological Surgery, The Cancer Institute Hospital of Japanese Foundation for Cancer Research0 个研究点目标入组 30 人开始时间: 2023年10月23日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •None of the following apply. 1) The patient is scheduled to undergo simultaneous resection for multiple cancers. 2) The patient has preoperative severe malnutrition or requires preoperative tube feeding. 3) The patient is undergoing emergency surgery. 4) The patient has been diagnosed with dementia. 5) The patient has psychosis or psychiatric symptoms. 6) Patient has a history of allergy to formula diets. 7) Patient is taking oral nutritional supplements or supplements. 8) Patient has a condition that the study physician deems inappropriate. 9) Patient does not give consent.
研究者
相似试验
进行中（未招募）
不适用
ocal treatment of bronchopleural fistula with adilts stem cellsEUCTR2012-000292-16-ESFundación para la Investigación Biomédica del Hospital Universitario La Paz (FIBHULP)
招募中
2 期
A phase II trial to reveal safety and efficacy of TM5509 in allogeneic stem cell transplantation with TBI regimeHematologic MalignancyJPRN-UMIN000018191Tohoku University School of Medicine, Molecular Medicine and Therapy, Toshio Miyata15
进行中（未招募）
1 期
A phase IIa clinical trial to demonstrate the proof of concept of an experimental pediculicide lotion for the treatment of head liceEUCTR2005-005512-24-GBEctoPharma Limited20
进行中（未招募）
1 期
Clinical Trial of allogeneic mesenchymal cells from umbilical cord tissue in patients with COVID-19.EUCTR2020-001450-22-ESFundación de Investigación del Hospital Infantil Universitario Niño Jesús106
进行中（未招募）
1 期
Clinical study to investigate whether the new drug (LEO 152020) is efficient and safe for the treatment of a special type of urticaria that is induced by sweating.cholinergic urticariaEUCTR2020-004961-38-DEEO Pharma A/S28